Skip to main content
Clinical Trials/NCT04072523
NCT04072523
Completed
Not Applicable

An Observational, Cross Sectional Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients in India

AstraZeneca1 site in 1 country621 target enrollmentDecember 3, 2019
ConditionsType 2 Diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
AstraZeneca
Enrollment
621
Locations
1
Primary Endpoint
Prevalence of Left Ventricular dysfunction
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

An Observational Study to assess the Prevalence of Heart Failure in Type 2 Diabetes Patients in India.

Detailed Description

This is a cross sectional, observational, multi-centre study to be conducted at 40 centres in India. The study targets to enrol 1000 patients with approx. 25 patients per site. The study would enrol Type 2 Diabetes Mellitus patients who provide written informed consent. No study medication will be prescribed or administered as a part of study procedure. Patients, who have been treated as per Investigators' routine clinical practice will be screened for enrolment in study. The study will be initiated after obtaining written approval of Independent Ethics Committee (IEC) /Institutional Review Board (IRB).

Registry
clinicaltrials.gov
Start Date
December 3, 2019
End Date
March 1, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Both men and women aged ≥ 18 years
  • Diagnosed with type 2 diabetes (as per ADA Criteria)
  • Duration of diabetes for 1 year or more
  • Willing to provide the informed consent

Exclusion Criteria

  • Patients with evidence of coronary artery disease - CAD (based on the clinical expertise of the physician).
  • Patients who were previously diagnosed with heart failure.
  • Patients with evidence of valvular disease based on clinical judgement of the Principle Investigator (PI).
  • Current treatment with digoxin.
  • History of symptoms of peripheral artery disease, chronic obstructive pulmonary disease and arrhythmias.
  • Patients diagnosed with stage III/IV CKD
  • Diabetes other than type 2 diabetes mellitus.

Outcomes

Primary Outcomes

Prevalence of Left Ventricular dysfunction

Time Frame: 1 day

based on the BNP levels and echocardiography results.

Secondary Outcomes

  • Correlation of Left ventricular dysfunction and heart failure(1 day)

Study Sites (1)

Loading locations...

Similar Trials